Astra Capital
Faralynn Wong
2025年8月12日
Boustead APEX, Inc. kicked off its inaugural China-wide IPO Conference in Shenzhen, the first of multiple city stops that will also include Beijing, Shanghai, and Hangzhou, bringing together entrepreneurs, investors, and market experts to share strategies for profitable growth and stronger positioning for U.S. capital market listings — while preserving founder equity.
FOR IMMEDIATE RELEASE
Shenzhen, China — 12 Aug 2025 — Boustead APEX, Inc. kicked off its inaugural China-wide IPO Conference in Shenzhen, the first of multiple city stops that will also include Beijing, Shanghai, and Hangzhou, bringing together entrepreneurs, investors, and market experts to share strategies for profitable growth and stronger positioning for U.S. capital market listings — while preserving founder equity.
The event spotlighted supply chain finance as a powerful tool to provide companies with working capital to fulfill confirmed sales orders. By converting orders into immediate cash flow, businesses can accelerate revenue growth, generate profits, and strengthen their position for high price-to-earnings (P/E) multiples and market capitalizations upon listing.
“Our mission is to empower founders to scale without losing control,” said Dr. Marcuz Tan (陳琛傑博士), CEO of Boustead APEX Inc. “Through supply chain finance, companies can boost profitability and position themselves for a significantly higher IPO valuation.”
Angela Ye (葉晨), Executive Director of Astra Capital, added:
“We advise on effective goods procurement to achieve positive cash flow and sustainable profitability — the foundation for higher P/E ratios and stronger market capitalization.”
Li Jing (李靜), CEO of Regen Health Care Group, affirmed:
“Adopting supply chain finance enhances our cash flow management, optimizes operations, and positions us for a high-valuation listing in the U.S.”
Boustead APEX also presented its integrated advisory roadmap — aiming to guide companies from profitability to U.S. listings on OTCQB, NASDAQ, or NYSE within an estimated 18–24 months.
Key Takeaways:
· Build revenues without diluting founder equity.
· Use supply chain finance to fund growth and drive profits.
· Translate operational success into a high-valuation public listing.
The Shenzhen conference reinforced Boustead APEX’s role in bridging Asia’s high-growth firms to the world’s largest capital markets while preserving founder ownership and maximizing returns.
Forward-Looking Statements
This release contains forward-looking statements, including potential benefits of supply chain finance, possible valuation outcomes, and indicative timelines for U.S. listings. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially. No assurance can be given that any particular result will be achieved. Factors that could affect outcomes include market conditions, regulatory approvals, the company’s financial performance, and other risks described in company disclosures. Readers should not place undue reliance on forward-looking statements and should consult qualified professional advisors.
Media Contact:
Faralynn Wong
Boustead APEX, Inc.
About Boustead APEX, Inc.
Boustead APEX, Inc. “BAI” provides corporate advisory services including but not limited to private-to-public listing strategy, mergers and acquisition deal structuring consultation, up-valuation and up-listing of undervalued companies.
About Astra Capital
Astra Capital provides online financial tools for global companies with trade finance advisory and funding arrangement services to help them grow their business. Astra Capital’s services range from issuance of letters of credit, bank guarantee, performance bond, pre-IPO funding, online crowdfunding, key-man universal life insurance, business credit/debit cards, asset digitalisation, e-wallet, e-vault, real estate investment trust, investment fund, issuance of public-listed companies’ B.O.S.S. (Bonds, Options, Shares & Structured-notes) and equities-backed financing.
About Regen Health Care Group
Regen Health Care Group is a leading provider of stem cell regeneration therapy, offering scientifically validated treatments designed to restore and repair damaged tissues and improve quality of life. Based in Shenzhen, China, Regen serves patients across Asia and is committed to advancing research in regenerative medicine.
Media Report:
宝德亚太深圳IPO大会聚焦供应链金融——助力企业实现高估值赴美上市
1、界面新闻：https://www.jiemian.com/article/13193084.html
2、凤凰财经：https://finance.ifeng.com/c/8lv6gnk04G4
3、证券之星：https://finance.stockstar.com/IG2025081800015920.shtml
4、和讯新闻：https://news.hexun.com/2025-08-18/220964616.html
5、财经网：http://industry.caijing.com.cn/20250818/5107821.shtml
6、中金在线：http://hy.stock.cnfol.com/hangyejingcui/20250818/31554918.shtml
7、新浪财经：https://finance.sina.com.cn//jjxw//2025-08-18//doc-infmmezw9779766.shtml